Celladon ($CLDN) has announced the beginning of a trial it hopes will determine the feasibility of using MYDICAR in heart failure patients using left ventricular assist devices (LVADs). MYDICAR, a treatment that uses targeted gene therapy to improve the heart's ability to pump blood, yielded positive results in previous trials with heart failure patients. The company hopes MYDICAR can provide a new option for patients with LVADs who have essentially exhausted all other treatment options, Celladon CEO Krisztina Zsebo said in a statement. Part of the funding from the trial will come from the British Heart Foundation, and it is being sponsored by the Imperial College of London. Release